The effects of anti-CD20 therapy on TFH cells in relapsing-remitting MS

This study presented at ECTRIMS examines the effect of anti-CD20 therapy on T follicular helper (TFH) cells in relapsing-remitting MS. Sahla El Mahdaoui explains how they found a reduction in CD25-negative TFH cells after treatment. These cells are enriched in cerebrospinal fluid in untreated MS patients and linked to disease activity. The findings suggest CD25-negative TFH cells may play a role in MS progression and treatment response.